FrancophonIA/ELRC3.0 huggingface dataset:
English: Rifampicin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect of EVOTAZ and development of resistance to atazanavir.
Slovenian: Rifampicin znatno zmanjša koncentracije atazanavirja v plazmi, kar lahko povzroči izgubo terapevtskega učinka zdravila EVOTAZ in razvoj odpornosti proti atazanavirju.
English: Atazanavir is metabolised and eliminated primarily by the liver.
Slovenian: Atazanavir se v glavnem presnavlja in izloča preko jeter.
English: EVOTAZ is not a cure for HIV infection.
Slovenian: Zdravilo EVOTAZ okužbe z virusom HIV ne ozdravi.
English: Patients were randomised in a 1:1 ratio to receive either atazanavir 300 mg with cobicistat 150 mg once daily or atazanavir 300 mg with ritonavir 100 mg once daily, each administered with a fixed background regimen containing tenofovir DF 300 mg and emtricitabine 200 mg administered as a fixed-dose combination tablet.
Slovenian: Bolnike so randomizirali v razmerju 1:1 tako, da so prejemali atazanavir v odmerku 300 mg s kobicistatom v odmerku 150 mg enkrat na dan ali atazanavir v odmerku 300 mg z ritonavirjem v odmerku 100 mg enkrat na dan, oboje s fiksnim osnovnim režimom, ki je vključeval 300 mg tenofovirja DF in 200 mg emtricitabina v obliki tablete s fiksno kombinacijo.
English: The mechanism of interaction between atazanavir/ritonavir and sofosbuvir/velpatasvir/voxilaprevir is inhibition of OATP1B, Pgp, and CYP3A.
Slovenian: Mehanizem interakcije med atazanavirjem/ritonavirjem in sofosbuvirjem/velpatasvirjem/ voksilaprevirjem je zaviranje OATP1B, Pgp in CYP3A.
English: Nevirapine AUC ↑25% (↑17%
Slovenian: Nevirapin AUC ↑25% (↑17%
English: The antiretroviral effect of EVOTAZ is due to the atazanavir component.
Slovenian: Protiretrovirusni učinek zdravila EVOTAZ je posledica atazanavirja.
English: Caution is warranted.
Slovenian: Navodilo shranite.
English: EVOTAZ must not be co-administered with colchicine to patients with renal or hepatic impairment.
Slovenian: Zdravila EVOTAZ se ne sme uporabljati skupaj s kolhicinom pri bolnikih z okvaro ledvic ali jeter.
English: It is unknown if cobicistat/metabolites are excreted in human milk.
Slovenian: Ni znano, ali se kobicistat/presnovki pri ljudeh izločajo v materino mleko.
English: Atazanavir was approximately 86% bound to human serum proteins over a concentration range of 100 to 10,000 ng/ml.
Slovenian: Vezava atazanavirja na serumske beljakovine pri človeku je v koncentracijskem razponu od 100 do 10.000 ng/ml približno 86-odstotna.
English: In 2 controlled clinical studies for combination therapy with other antiretroviral medicinal products 1,806 adult patients receiving atazanavir 400 mg once daily (1,151 patients, 52 weeks median duration and 152 weeks maximum duration) or atazanavir 300 mg boosted with ritonavir 100 mg once daily (655 patients, 96 weeks median duration and 108 weeks maximum duration), the most frequently reported adverse reactions were nausea, diarrhoea and jaundice.
Slovenian: V 2 nadzorovanih kliničnih študijah kombiniranega zdravljenja z drugimi protiretrovirusnimi zdravili je 1.806 odraslih bolnikov prejemalo atazanavir v odmerku 400 mg enkrat na dan (1.151 bolnikov, mediano trajanje zdravljenja 52 tednov, najdaljše trajanje zdravljenja 152 tednov) ali atazanavir v odmerku 300 mg, okrepljen z ritonavirjem 100 mg enkrat na dan (655 bolnikov, mediano trajanje zdravljenja 96 tednov, najdaljše trajanje zdravljenja 108 tednov).
English: There are currently inadequate data to determine whether co-administration of tenofovir disoproxil and cobicistat is associated with a greater risk of renal adverse reactions compared with regimens that include tenofovir disoproxil without cobicistat.
Slovenian: Na osnovi trenutno razpoložljivih podatkov ni mogoče oceniti, če je sočasna uporaba dizoproksiltenofovirata in kobicistata morda povezana z večjim tveganjem za pojav neželenih učinkov za ledvice v primerjavi s shemami zdravljenja, ki vključujejo dizoproksiltenofovirat brez kobicistata.
English: Voriconazole should not be co-administered with EVOTAZ unless the benefit/risk assessment justifies the use of voriconazole (see section 4.4).
Slovenian: Vorikonazola se ne sme uporabljati sočasno z zdravilom EVOTAZ, razen če ocena koristi/tveganj upravičuje uporabo vorikonazola (glejte poglavje 4.4).
English: When administered in combination, no clear additive or synergistic cardiovascular effects were observed at atazanavir and cobicistat concentrations at least 2-fold higher than the free atazanavir and cobicistat concentrations at the RHD Cmax.
Slovenian: Pri kombinirani uporabi niso opazili jasnih aditivnih ali sinergističnih kardiovaskularnih učinkov pri koncentracijah atazanavirja in kobicistata, ki so bile vsaj 2-krat večje od koncentracij Cmax prostega atazanavirja in kobicistata pri uporabi priporočenega odmerka za človeka.
English: If signs or symptoms of cholelithiasis occurs, temporary interruption or discontinuation of treatment may be considered.
Slovenian: Če se pojavijo znaki ali simptomi holelitiaze, je treba razmisliti o začasni prekinitvi ali trajni ukinitvi zdravljenja.
English: Sildenafil, tadalafil, and vardenafil are metabolised by CYP3A4.
Slovenian: Sildenafil, tadalafil in vardenafil se presnavljajo s CYP3A4.
English: Effects unknown
Slovenian: Neželeni učinek
English: This may result in loss of therapeutic effect of EVOTAZ and development of resistance to atazanavir (see section 4.4).
Slovenian: Zaradi tega lahko pride do izgube terapevtskega učinka zdravila EVOTAZ in razvoja odpornosti proti atazanavirju (glejte poglavje 4.4).
English: Atazanavir was negative in an Ames reverse-mutation assay but did induce chromosomal aberrations in vitro in both the absence and presence of metabolic activation.
Slovenian: Amesov test reverznih mutacij je bil za atazanavir negativen, toda in vitro so odkrili pojav kromosomskih aberacij, in sicer tako s presnovno aktivacijo kot brez nje.
English: If signs or symptoms of nephrolithiasis occurs, temporary interruption or discontinuation of treatment may be considered.
Slovenian: Če se pojavijo znaki ali simptomi nefrolitiaze, je treba razmisliti o začasni prekinitvi ali trajni ukinitvi zdravljenja.
English: Tenofovir alafenamide AUC ↑75% (↑55% ↑98%) Cmax ↑80% (↑48% ↑118%)
Slovenian: Alafenamidtenofovirat AUC ↑75% (↑55% ↑98%) Cmax ↑80% (↑48% ↑118%)
English: Co-administration of nevirapine and EVOTAZ is expected to increase nevirapine plasma concentrations which may increase the risk of nevirapine-associated toxicity (see section 4.4).
Slovenian: Pri sočasni uporabi nevirapina in zdravila EVOTAZ pričakujemo povečanje koncentracij nevirapina v plazmi, kar lahko poveča tveganje za pojav z nevirapinom povezane toksičnosti (glejte poglavje 4.4).
English: Maraviroc
Slovenian: Maravirok
English: f Plus background regimen of emtricitabine 200 mg and tenofovir DF 300 mg fixed-dose combination.
Slovenian: f In osnovni režim s fiksno kombinacijo 200 mg emtricitabina in 300 mg tenofovirja DF.
English: Immune reactivation syndrome and autoimmune disorders
Slovenian: Sindrom imunske reaktivacije in avtoimunske bolezni
English: Ex vivo rabbit studies and in vivo dog studies suggest that cobicistat has a low potential for QT prolongation, and may slightly prolong the PR interval and decrease left ventricular function at mean concentrations at least 10-fold higher than the human exposure at the recommended 150 mg daily dose.
Slovenian: Študije pri kuncih ex vivo in pri psih in vivo kažejo, da ima kobicistat pri povprečnih koncentracijah, ki so vsaj 10-krat večje od izpostavljenosti človeka pri uporabi priporočenega dnevnega odmerka 150 mg, majhen potencial za podaljšanje intervala QT, da lahko nekoliko podaljša interval PR ter zmanjša delovanje levega prekata.
English: There are limited data from the use of EVOTAZ in pregnant women.
Slovenian: Podatki o uporabi zdravila EVOTAZ pri nosečnicah so omejeni.
English: Wait and take the next dose at the usual time.
Slovenian: Nadaljevati mora le z jemanjem zdravila ob običajnem času.
English: In clinical study GS-US-216-0114, a phase 3 randomised, active-controlled clinical study, in which 692 treatment-naïve patients received at least one dose of atazanavir boosted with cobicistat (n = 344) or atazanavir boosted with ritonavir (n = 348) administered with other antiretroviral medicinal products, the most frequently reported adverse reactions in the atazanavir boosted with cobicistat group during 144 weeks were associated with elevated bilirubin levels (see Table 2).
Slovenian: V randomizirani, z učinkovino nadzorovani klinični študiji 3. faze GS-US-216-0114, v kateri je 692 predhodno nezdravljenih bolnikov prejelo vsaj en odmerek atazanavirja, okrepljenega s kobicistatom (n = 344), ali vsaj en odmerek atazanavirja, okrepljenega z ritonavirjem (n = 348), sočasno z drugimi protiretrovirusnimi zdravili, so v skupini, ki je prejemala atazanavir, okrepljen s kobicistatom, med 144 tedni zdravljenja najpogosteje poročali o neželenih učinkih, ki so bili povezani z zvišanjem vrednosti bilirubina (glejte tabelo 2).
English: The mechanism of interaction is CYP3A induction by the antiepileptic.
Slovenian: Mehanizem interakcije je indukcija CYP3A z antiepileptiki.
English: Each single agent produced effects on left ventricular contractility and PR prolongation at concentrations at least 35-fold higher than the free atazanavir and cobicistat concentrations at the recommended human dose (RHD) Cmax.
Slovenian: Vsaka posamezna učinkovina je imela učinke na kontraktilnost levega prekata in podaljšanje intervala PR pri koncentracijah, ki so bile vsaj 35-krat večje od koncentracij Cmax prostega atazanavirja in kobicistata pri uporabi priporočenega odmerka za človeka.
English: Cobicistat: AUC: ↔ Cmax: ↔ Cmin: ↓66%
Slovenian: Kobicistat: AUC: ↔ Cmax: ↔ Cmin: ↓66%
English: HERBAL PRODUCTS St. John's wort (Hypericum perforatum)
Slovenian: ZDRAVILA RASTLINSKEGA IZVORA Šentjanževka (Hypericum perforatum)
English: Atazanavir is metabolised principally by CYP3A4.
Slovenian: Atazanavir se v glavnem presnavlja s CYP3A4.
English: Following oral administration of [14C]cobicistat, 86% and 8.2% of the dose were recovered in faeces and urine, respectively.
Slovenian: Pri peroralni uporabi [14C]kobicistata se je 86 % odmerka izločilo z blatom, 8,2 % pa z urinom.
English: Co-administration of EVOTAZ and rifabutin is not recommended.
Slovenian: Sočasna uporaba zdravila EVOTAZ in rifabutina ni priporočljiva.
English: How to store EVOTAZ 6.
Slovenian: Shranjevanje zdravila EVOTAZ 6.
English: The pharmacokinetics of atazanavir and cobicistat, alone or in combination, have not been evaluated in an elderly population (65 years of age and older).
Slovenian: Pri starostnikih (osebe, stare 65 let ali starejše) farmakokinetike atazanavirja in kobicistata, samih ali v kombinaciji, niso vrednotili.
English: EVOTAZ is to be taken orally with food (see section 5.2).
Slovenian: Bolnik mora zdravilo EVOTAZ jemati peroralno skupaj s hrano (glejte poglavje 5.2).
English: H2-Receptor antagonists
Slovenian: Antagonisti histaminskih receptorjev H2
English: Some examples include, but are not limited to, itraconazole, ketoconazole and voriconazole (see Table 1).
Slovenian: Takšna zdravila so med drugimi itrakonazol, ketokonazol in vorikonazol (glejte tabelo 1).
English: Medicinal products that may be affected by atazanavir/cobicistat Atazanavir is an inhibitor of CYP3A4 and UGT1A1.
Slovenian: Zdravila, na katera lahko vpliva atazanavir/kobicistat Atazanavir je zaviralec CYP3A4 in UGT1A1.
English: In female mice, atazanavir exposure at a dose that produced single-cell necrosis was 12 times the exposure in humans given 400 mg once daily.
Slovenian: Pri mišjih samicah je bila izpostavljenost atazanavirju pri odmerku, ki je povzročil nekrozo posameznih jetrnih celic, 12-krat večja od izpostavljenosti človeka pri uporabi odmerka 400 mg enkrat na dan.
English: 14-OH clarithromycin Cmax ↓72%
Slovenian: 14-OH klaritromicin Cmax ↓72%
English: Administration of a single dose of EVOTAZ with a high fat meal (1,038 kcal, 59 g fat, 37 g protein) resulted in a 14% reduction in atazanavir Cmax with no change in atazanavir AUC or cobicistat exposures (Cmax, AUC) relative to the fasting state.
Slovenian: Pri uporabi enkratnega odmerka zdravila EVOTAZ skupaj s hrano z visoko vsebnostjo maščob (1.038 kcal, 59 g maščob, 37 g beljakovin) se je vrednost Cmax atazanavirja zmanjšala za 14 %, vrednost AUC atazanavirja ali izpostavljenost kobicistatu (Cmax, AUC) pa se ni spremenila v primerjavi z uporabo na tešče.
English: It is recommended that women infected with HIV do not breast-feed because the virus might be transmitted through the breast milk.
Slovenian: Ženskam, okuženim z virusom HIV, zaradi možnosti prenosa virusa z mlekom ne priporočamo dojenja.
English: Digoxin (0.5 mg single dose)/cobicistat (150 mg multiple doses)
Slovenian: Digoksin (0,5 mg enkratni odmerek)/kobicistat (150 mg ponavljajoči se odmerki)
English: The 24-hour atazanavir concentration following a high-fat meal was increased approximately 23% due to delayed absorption; the median Tmax increased from 2.0 to 3.5 hours.
Slovenian: Po obroku z visoko vsebnostjo maščob se je 24-urna koncentracija atazanavirja zaradi zakasnele absorpcije povečala za približno 23 %.
English: Cobicistat has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine without affecting actual renal glomerular function.
Slovenian: Dokazano je bilo, da kobicistat zmanjša ocenjeni kreatininski očistek, kar je posledica zaviranja tubulne sekrecije kreatinina brez vpliva na dejansko ledvično glomerulno funkcijo.
English: 14-OH clarithromycin Cmin ↓62%
Slovenian: 14-OH klaritromicin Cmin ↓62%
English: Buprenorphine AUC: ↑35% Buprenorphine Cmax: ↑66% Buprenorphine Cmin: ↑12%
Slovenian: Buprenorfin AUC: ↑35% Buprenorfin Cmax: ↑66% Buprenorfin Cmin: ↑12%
English: There are no pharmacokinetic data regarding the use of EVOTAZ in patients with hepatic impairment.
Slovenian: Farmakokinetični podatki o uporabi zdravila EVOTAZ pri bolnikih z okvaro jeter niso na voljo.
English: Atazanavir, a component of EVOTAZ is excreted in human milk.
Slovenian: Atazanavir, sestavina zdravila EVOTAZ, se izloča v materino mleko.
English: Co-administration of nevirapine and cobicistat is expected to decrease cobicistat plasma concentrations while nevirapine plasma concentrations may be increased.
Slovenian: Pri sočasni uporabi nevirapina in kobicistata pričakujemo zmanjšanje koncentracij kobicistata v plazmi, koncentracije nevirapina v plazmi pa se lahko povečajo.
English: Co-administration of EVOTAZ with these medicinal products is expected to substantially increase their concentrations and may result in PDE5-associated adverse reactions such as hypotension, visual changes and priapism (see section 4.5).
Slovenian: Pri sočasni uporabi zdravila EVOTAZ in teh zdravil pričakujemo znaten porast njihovih koncentracij, kar posledično lahko privede do pojava neželenih učinkov zaviralcev PDE5, kot so hipotenzija, spremembe vida in priapizem (glejte poglavje 4.5).
English: Co- administration of EVOTAZ and ticagrelor may increase concentrations of the anticoagulant.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ in ticagrelorja se koncentracije antikoagulansa lahko povečajo.
English: EVOTAZ should not be initiated in patients with creatinine clearance less than 70 ml/min if any co-administered agent (e.g. emtricitabine, lamivudine, tenofovir disoproxil or adefovir) requires dose adjustment based on creatinine clearance (see sections 4.4, 4.8 and 5.2).
Slovenian: Zdravljenja z zdravilom EVOTAZ se ne sme uvesti pri bolnikih s kreatininskim očistkom, manjšim od 70 ml/min, če je odmerek katerega koli sočasno uporabljenega zdravila (npr. emtricitabin, lamivudin, dizoproksiltenofovirat ali adefovir) treba prilagoditi na osnovi kreatininskega očistka (glejte poglavja 4.4, 4.8 in 5.2).
English: Nevirapine Cmax ↑17% (↑9%
Slovenian: Nevirapin Cmax ↑17% (↑9%
English: Contraindicated because of the potential increase in the risk of ALT elevations due to a significant increase in glecaprevir and pibrentasvir plasma concentrations (see section 4.3)
Slovenian: Sočasna uporaba je kontraindicirana zaradi možnega večjega tveganja za zvišanje vrednosti ALT zaradi pomembnega povečanja koncentracij glekaprevirja in pibrentasvirja v plazmi (glejte poglavje 4.3).
English: Nevirapine Cmin ↑32% (↑22%
Slovenian: Nevirapin Cmin ↑32% (↑22%
English: Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.
Slovenian: Bolnikom je treba pojasniti, da morajo v primeru pojava bolečine v sklepih, togosti sklepov ali težav z gibljivostjo poiskati zdravniško pomoč.
English: Telaprevir 750 mg three times daily (cobicistat 150 mg once daily in combination with elvitegravir)
Slovenian: Telaprevir 750 mg trikrat na dan (kobicistat 150 mg enkrat na dan v kombinaciji z elvitegravirjem)
English: Co-administration of EVOTAZ with medicinal products that inhibit CYP3A may decrease the clearance of atazanavir and cobicistat, resulting in increased atazanavir and cobicistat plasma concentrations (see section 4.5).
Slovenian: Pri sočasni uporabi zdravila EVOTAZ in zdravil, ki zavirajo CYP3A, se lahko zmanjša očistek atazanavirja in kobicistata, zaradi česar se lahko povečajo koncentracije atazanavirja in kobicistata v plazmi (glejte poglavje 4.5).
English: However, patients should be informed that dizziness has been reported during treatment with regimens containing atazanavir or cobicistat (see section 4.8).
Slovenian: Vendar pa je bolnikom treba pojasniti, da so med zdravljenjem z atazanavirjem ali s kobicistatom poročali o pojavu omotice (glejte poglavje 4.8).
English: Co-administration with the following medicinal products that are strong inducers of the CYP3A4 isoform of cytochrome P450 due to the potential for loss of therapeutic effect (see section 4.5): carbamazepine, phenobarbital, phenytoin (antiepileptics) St John's wort (Hypericum perforatum) (herbal product) rifampicin (antimycobacterial)
Slovenian: Sočasna uporaba z naslednjimi zdravili, ki so močni induktorji izooblike CYP3A4 citokroma P450, zaradi možne izgube terapevtskega učinka (glejte poglavje 4.5): karbamazepin, fenobarbital in fenitoin (antiepileptiki).
English: Cobicistat does not select any HIV resistance mutations, due to its lack of antiviral activity.
Slovenian: Kobicistat nima protivirusne aktivnosti, zato ne povzroča rezistenčnih mutacij virusa HIV.
English: Administration of a single dose of EVOTAZ with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 42% increase in atazanavir Cmax, a 28% increase in atazanavir AUC, a 31% increase in cobicistat Cmax, and a 24% increase in cobicistat AUC relative to the fasting state.
Slovenian: Pri uporabi enkratnega odmerka zdravila EVOTAZ skupaj z lahkim obrokom (336 kcal, 5,1 g maščob, 9,3 g beljakovin) se je vrednost Cmax atazanavirja povečala za 42 %, vrednost AUC atazanavirja za 28 %, vrednost Cmax kobicistata za 31 %, vrednost AUC kobicistata pa za 24 % v primerjavi z uporabo na tešče.
English: Serious skin rash, including Stevens-Johnson syndrome, may develop in patients taking EVOTAZ.
Slovenian: Pri bolnikih, ki se zdravijo z zdravilom EVOTAZ, se lahko pojavi resen kožni izpuščaj, vključno s Stevens-Johnsonovim sindromom.
English: Concentrations of ketoconazole, itraconazole, and/or cobicistat may be increased with co-administration of ketoconazole or itraconazole with EVOTAZ.
Slovenian: Pri sočasni uporabi ketokonazola ali itrakonazola in zdravila EVOTAZ se koncentracije ketokonazola, itrakonazola in/ali kobicistata lahko povečajo.
English: Co-administration of EVOTAZ with grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination (used to treat chronic hepatitis C infection) is contraindicated because of the increase in grazoprevir and elbasvir plasma concentrations and potential for the increase in risk of ALT elevations associated with the increase in grazoprevir concentrations (see section 4.3 and Table 1).
Slovenian: Sočasna uporaba zdravila EVOTAZ in zdravil, ki vsebujejo grazoprevir, vključno s fiksno kombinacijo elbasvir/grazoprevir (uporabljamo jih za zdravljenje kronične okužbe z virusom hepatitisa C) je kontraindicirana zaradi povečanja koncentracij grazoprevirja in elbasvirja v plazmi in možnega večjega tveganja za zvišanje vrednosti ALT, povezanega s povečanimi koncentracijami grazoprevirja (glejte poglavje 4.3 in tabelo 1).
English: No significant effect on atazanavir concentrations was observed.
Slovenian: Pomembnih učinkov na koncentracije atazanavirja niso opazili.
English: In a nonclinical fertility and early embryonic development study in rats, atazanavir altered oestrus cycling with no effects on mating or fertility (see section 5.3).
Slovenian: Atazanavir je v predkliničnih študijah plodnosti in zgodnjega embrionalnega razvoja pri podganah spremenil estrusni ciklus brez učinkov na parjenje ali plodnost (glejte poglavje 5.3).
English: perphenazine, risperidone, thioridazine, midazolam (given by injection), buspirone, clorazepate, diazepam, estazolam, flurazepam and zolpidem (used to treat nevous system disorders) buprenorphine (used to treat opioid addiction and pain)
Slovenian: perfenazin, risperidon, tioridazin, midazolam (v obliki injekcij), buspiron, klorazepat, diazepam, estazolam, flurazepam in zolpidem (uporabljamo jih za zdravljenje bolezni živčevja).
English: Co-administration of EVOTAZ with voxilaprevir-containing products is expected to increase the concentration of voxilaprevir.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ in zdravil, ki vsebujejo voksilaprevir, je pričakovati povečanje koncentracij voksilaprevirja.
English: Midazolam and triazolam are extensively metabolized by CYP3A4.
Slovenian: Midazolam in triazolam se v obsežno presnavljata s CYP3A4.
English: Cobicistat is metabolised via CYP3A (major)- and CYP2D6 (minor)-mediated oxidation and does not undergo glucuronidation.
Slovenian: Kobicistat se presnavlja z oksidacijo, pri kateri sodelujeta CYP3A (glavna pot) in CYP2D6 (manj pomembna pot), in se ne glukuronidira.
English: Gastrointestinal disorders very common nausea common vomiting, diarrhoea, dyspepsia, abdominal pain, abdominal distension, flatulence, dry mouth uncommon pancreatitis, gastritis, stomatitis aphthous
Slovenian: Bolezni prebavil zelo pogosti navzea pogosti bruhanje, driska, dispepsija, bolečina v trebuhu, napihnjenost trebuha, flatulenca, suha usta občasni pankreatitis, gastritis, aftozni stomatitis
English: Clinical monitoring may be needed upon co-administration with EVOTAZ.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ bo morda potreben klinični nadzor.
English: NEUROLEPTICS Perphenazine Risperidone Thioridazine
Slovenian: NEVROLEPTIKI Perfenazin Risperidon Tioridazin
English: There are limited clinical data with cobicistat in pregnant women.
Slovenian: Klinični podatki o uporabi kobicistata pri nosečnicah so omejeni.
English: Medicinal products that affect atazanavir/cobicistat exposure Atazanavir is metabolised in the liver through CYP3A4.
Slovenian: Zdravila, ki vplivajo na izpostavljenost atazanavirju/kobicistatu Atazanavir se presnavlja v jetrih s CYP3A4.
English: Combinations of EVOTAZ and indinavir have not been studied and co-administration of these medicinal products is not recommended (see section 4.5).
Slovenian: Uporabe zdravila EVOTAZ v kombinaciji z indinavirjem niso raziskovali, zato sočasna uporaba teh zdravil ni priporočljiva (glejte poglavje 4.5).
English: Do not take EVOTAZ: if you are allergic to atazanavir, cobicistat or any of the other ingredients of this medicine (listed in section 6) if you have moderate to severe liver problems if you are taking any of these medicines: see also Other medicines and EVOTAZ
Slovenian: Ne jemljite zdravila EVOTAZ: če ste alergični na atazanavir, kobicistat ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: Cobicistat is primarily metabolised and eliminated by the liver.
Slovenian: Kobicistat se v glavnem presnavlja in izloča preko jeter.